—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Eli Lilly and Company (LLY) — chart, structure and Closelooknet read

The Closelooknet read

Eli Lilly discovers, develops and markets pharmaceutical products across cardiometabolic health, oncology, immunology and neuroscience, including insulin lines, Mounjaro, Trulicity, Zepbound, Verzenio and Ebglyss. It sells in the United States, Europe, China, Japan and other markets, often through collaborations and licensing deals with other firms.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

The desk on LLY

What this diary said about Eli Lilly and Company, what it holds and what would change its view — in its own words, dated. Investment diary, not advice.

What we hold

BookPositionSinceResult
Hypergrowth 15.05 shares · average entry $1,016.68 — +40.8%
The Compound (wikifolio) ↗ 3 shares · average entry €1,055.60 — —

Model books as of 10 Nov 2026; wikifolio positions from the official wikifolio data, entries in euros. Results are unrealised, before any exit. A record of what the diary does, not a recommendation to do the same.

Our record on LLY

Every scored call, pick and trade this diary has made on Eli Lilly and Company, with the outcome where it is known.

Signals for this name

Every Closelooknet reading that exists for LLY, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index HALO Growth 100 · AI Users — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

HALO Growth 100 · as of 2026-11-10

DayWeekMonth3 months
LLY+1.4%+1.6%+21.1%+17.4%
Longevity & Healthspan−0.3%−1.6%+3.9%—
HALO Growth 100−1.0%−0.1%+1.9%—

Against the index: 1.7 pts ahead on the week, 19.2 pts ahead on the month; against its Longevity & Healthspan sleeve 17.2 pts ahead on the month.

AI Users · as of 2026-11-10

DayWeekMonth3 months
LLY+1.4%+1.6%+21.1%+17.5%
Research, Design & Development−0.2%−2.8%+8.0%—
AI Users−0.1%+1.1%+5.5%—

Against the index: 0.5 pts ahead on the week, 15.6 pts ahead on the month; against its Research, Design & Development sleeve 13.1 pts ahead on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Mentioned on Closelooknet 8 pieces · newest: Midday 10, “Oil — Brent −6.5% on Iran Talks Lifts Stocks; Amazon +5%, Oracle −6% on a $20 Billion Raise” (2026-11-02)

Mentioned on Closelooknet

Where LLY appears in the diary — 8 pieces, newest first. Every link is our own writing.

Long reads

Dailies

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 48/100 · S&P 500 fund at 51, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-10
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 67th percentile of the window, -18.1% over 20 sessions. Factor regime → 2026-11-10
  • Sovereign pressure Index -1.67 · down 1.71 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-09
How it trades on rate days beta 0.61 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How LLY has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.61 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Eli Lilly and Company moved 0.61% on average · correlation 0.17 · higher than 51% of US names
  • Beta, last 3 months 1.12 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.36% on average against −0.72% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +1.44% TLT −1.32% that day 2026-11-10

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against HALO Growth 100 · Longevity & Healthspan · 8 names with week and year-to-date

Peer group

HALO Growth 100 · Longevity & Healthspan

GLP-1 leaders, gene-editing platforms, diagnostics-at-scale, biopharma compounders. Demographics writes the demand curve.

Compared against LLY on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Eli Lilly and Company

LLY in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Eli Lilly discovers, develops and markets pharmaceutical products across cardiometabolic health, oncology, immunology and neuroscience, including insulin lines, Mounjaro, Trulicity, Zepbound, Verzenio and Ebglyss. It sells in the United States, Europe, China, Japan and other markets, often through collaborations and licensing deals with other firms. It is headquartered in Indianapolis.
Where it sits in the stack
Lilly sits in Closelooknet's AI Users index, in the Research, Design & Development section, which tracks firms applying AI to discovery and engineering rather than building the infrastructure behind it. It disclosed in September 2025 that TuneLab, models trained on internal data, predicts ADME and safety properties and is used daily by its scientists, assisting researchers rather than deciding on its own.
Who it is priced against
Closelooknet groups it in the HALO Growth 100's Longevity & Healthspan sleeve, alongside GLP-1 leaders, gene-editing platforms, diagnostics-at-scale and biopharma compounders such as Novo Nordisk, Amgen, Regeneron, Vertex, Zealand Pharma, Illumina, Natera and Gerresheimer; the market also names AbbVie as a comparator.
Why Closelooknet tracks it
It is a HALO Growth 100 constituent and carries a Closelooknet score across three modules, strongest on quality and weakest on valuation; the Midday 10 has quoted it on a session where it lagged the Health Care sector.
What the diary watches
The diary watches whether Lilly's planned AI factory, announced in October 2025 to run scientific and enterprise agents alongside manufacturing digital twins and imaging for 2026, moves from construction into actual use.

Eli Lilly and Company (LLY) trades on US exchanges, classified under Healthcare. Constituent of HALO Growth 100.

The Closelooknet company score reads 64/100 composite (momentum 91, quality 90, valuation 22) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-10-25. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: LLY news on the tape · index compare · sector dispersion · scanner.

The Street on this name 6 analyst actions on the wire · latest: price target by Freedom Broker, 2026-10-30 · last print 2026-10-29

The Street on this name

Analyst actions and the latest print for LLY from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Freedom Broker — target 1,600 Target set to $1600 (+12.3% to spot) 2026-10-30
  • Price target Argus — target 1,550 Target set to $1550 (+12.9% to spot) 2026-10-30
  • Price target Bernstein — target 1,450 from 1,385 Target raised to $1450 from $1385 (+13.9% to spot) 2026-10-26
  • Latest print EPS 7.48 against 5.71 expected — a +31.0% beat 2026-10-29

6 actions on the analyst wire since 2026-08-13: 1 upgrade, 5 target changes. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 0.47%, quarterly · buybacks 4.11 bn USD in FY2025

Dividends and capital return

What LLY pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 6.69 USD per share · a 0.47% yield on the 2026-11-10 close 4 distributions, paid quarterly 2026-11-10
  • Change on the year +15.3% against the prior twelve months prior twelve months 5.80 USD per share
  • Last distribution 1.73 USD per share as the price series records it, within days of the ex-date 2026-08-14
  • By calendar year 2023: 1.13 USD (partial) · 2024: 5.20 USD · 2025: 6.00 USD · 2026: 5.19 USD to date first distribution recorded in the three-year window: 2023-11-14
  • Dividends paid, FY2025 5.38 bn USD 22% of earnings
  • Buybacks, FY2025 4.11 bn USD 0.3% of today's market value
  • Share count −0.7% in FY2025 626 m USD of stock-based compensation in the year
  • Capital returned 9.49 bn USD · 106% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-11

Quick answers

What is Eli Lilly and Company (LLY)?

Eli Lilly and Company trades as LLY on the US exchange and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-11.

Is LLY in a Closelooknet index?

Yes — Eli Lilly and Company is a constituent of HALO Growth 100, as of 2026-11-11.

What is Eli Lilly and Company's Closelooknet composite score?

64 out of 100, with momentum 91, quality 90 and valuation 22 sub-scores, as of 2026-11-11. Scores are Closelooknet's own research readings, not ratings or investment advice.

What is Eli Lilly and Company's earnings print record?

Across the 11 prints Closelooknet covers, Eli Lilly and Company beat EPS estimates 10 times and revenue estimates 9 times; the three-day reactions split 5 up, 3 flat and 3 down (moves beyond ±3%), as of the 2026-10-22 card. The full print-record card carries the per-print history.

Where does LLY trade against its moving averages?

Eli Lilly and Company trades 15.8% above its 50-day and 28.2% above its 200-day moving average (7.5% above its 20-day). As of 2026-11-09 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is LLY doing against its Closelooknet index?

Over the past month Eli Lilly and Company is +21.1% against +1.9% for the HALO Growth 100 — 19.2 points ahead of its index, as of 2026-11-10. Its Longevity & Healthspan sleeve is +3.9% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

How does Eli Lilly and Company compare with its peers?

Against its peer group (HALO Growth 100 · Longevity & Healthspan), Eli Lilly and Company (LLY) sits 2.8% below its 52-week high, 15.8% above its 50-day average; Regeneron Pharmaceuticals Inc (REGN) is 7.2% below, Zealand Pharma A/S (ZEAL.CO) is 55.9% below, Illumina Inc (ILMN) is 28.6% below, as of 2026-11-09. Put any of them next to LLY in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Eli Lilly and Company trade when bond yields rise?

Over the past year Eli Lilly and Company had a beta of 0.61 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 51% of US names. On the 10 sessions in which long bonds fell most it moved −0.36% on average, against −0.72% for the S&P 500. As of 2026-11-10; The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Eli Lilly and Company?

Eli Lilly and Company appears in 8 Closelooknet pieces as of 2026-11-11, most recently Midday 10: Oil — Brent −6.5% on Iran Talks Lifts Stocks; Amazon +5%, Oracle −6% on a $20 Billion Raise (2026-11-02); Midday 10: Sell-Off — Nasdaq −3%, Chips −8%, Bitcoin −4%, Gold −3%; Only Bonds, Oil and Defensives Hold (2026-10-30); Report: AI Users — Builders Up 66%, the Companies Using AI Flat (2026-10-25). What Closelooknet said most recently: LLY slips 2.85 percent to 1116.13 and crosses below its 50-day average, bearing a disproportionate share of Health Care's weakness — two days before it prints into the calmest reaction record this series covers. (Midday 10, 2026-08-03). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

Does Closelooknet hold Eli Lilly and Company?

Yes — Hypergrowth: 15.05 shares · average entry $1,016.68, +40.8% unrealised (book of 2026-11-10); The Compound (wikifolio): 3 shares · average entry €1,055.60 (book of 2026-11-10). A record of what the diary does, not a recommendation to do the same.

What does Eli Lilly and Company do?

Eli Lilly discovers, develops and markets pharmaceutical products across cardiometabolic health, oncology, immunology and neuroscience, including insulin lines, Mounjaro, Trulicity, Zepbound, Verzenio and Ebglyss. It sells in the United States, Europe, China, Japan and other markets, often through collaborations and licensing deals with other firms. It is headquartered in Indianapolis. Closelooknet groups it in the HALO Growth 100's Longevity & Healthspan sleeve, alongside GLP-1 leaders, gene-editing platforms, diagnostics-at-scale and biopharma compounders such as Novo Nordisk, Amgen, Regeneron, Vertex, Zealand Pharma, Illumina, Natera and Gerresheimer; the market also names AbbVie as a comparator. (Company snapshot of 2026-10-25.)

Where does Eli Lilly and Company sit in the AI build-out?

Lilly sits in Closelooknet's AI Users index, in the Research, Design & Development section, which tracks firms applying AI to discovery and engineering rather than building the infrastructure behind it. It disclosed in September 2025 that TuneLab, models trained on internal data, predicts ADME and safety properties and is used daily by its scientists, assisting researchers rather than deciding on its own. It is a HALO Growth 100 constituent and carries a Closelooknet score across three modules, strongest on quality and weakest on valuation; the Midday 10 has quoted it on a session where it lagged the Health Care sector. (Company snapshot of 2026-10-25.)

Does Eli Lilly and Company pay a dividend?

Eli Lilly and Company has paid 6.69 USD per share over the last twelve months, paid quarterly, a trailing yield of 0.47% on the 2026-11-10 close; the last distribution recorded in the price series was 1.73 USD on 2026-08-14. In fiscal 2025 the company paid 5.38 bn USD in dividends and bought back 4.11 bn USD of its own shares, 106% of that year’s free cash flow. The share count fell 0.7% over the fiscal year. As of 2026-11-10; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Eli Lilly and Company recently?

The most recent analyst action on Eli Lilly and Company on the Closelooknet wire is a price target by Freedom Broker on 2026-10-30 (target 1,600). 6 actions on the analyst wire since 2026-08-13: 1 upgrade, 5 target changes. Its latest earnings print on the wire, 2026-10-29: EPS 7.48 against 5.71 expected — a +31.0% beat. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for LLY, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

same Closelooknet index seat first, then Drug Manufacturers - General. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.